Compare AMCI & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMCI | RANI |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.0M | 126.8M |
| IPO Year | N/A | 2021 |
| Metric | AMCI | RANI |
|---|---|---|
| Price | $7.14 | $1.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 50.6K | ★ 740.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.05 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,028,000.00 |
| Revenue This Year | N/A | $414.59 |
| Revenue Next Year | N/A | $30.15 |
| P/E Ratio | $33.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.60 | $0.39 |
| 52 Week High | $15.75 | $3.87 |
| Indicator | AMCI | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 56.48 | 51.64 |
| Support Level | $5.84 | $1.31 |
| Resistance Level | $7.75 | $1.42 |
| Average True Range (ATR) | 0.66 | 0.08 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 74.62 | 61.76 |
AMC Robotics Corp is an artificial intelligence services company that develops robotic solutions designed to support operational efficiency across sectors such as logistics and manufacturing. The company develops robotics and automation technologies designed to improve logistics operations. Its robots use sensors and visual AI to support real-time decision-making, contributing to safer and more efficient warehouse operations. It builds autonomous robots for use in logistics and warehousing.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.